Abstract BACKGROUND: Recent studies have shown that several tumours express c-KIT, a growth factor receptor with tyrosine kinase activity; moreover, clinical results have shown the efficacy of the tyrosine kinase inhibitor, STI571, in c-KIT-positive tumours. The aim of this study was to determine the incidence and correlation with chemotherapy resistance of c-KIT expression in advanced serous, low grade of differentiation, ovarian carcinoma. PATIENTS AND METHODS: We performed an immunohistochemistry analysis of 56 patients with advanced serous ovarian carcinomas using archival paraffin-embedded specimens. RESULTS: Intense c-KIT immunostaining was observed in 51.7% of cases. c-KIT expression was statistically correlated with progression of disease after first-line chemotherapy (P = 0.029). CONCLUSIONS: c-KIT is also expressed in ovarian carcinoma and it is statistically correlated with chemotherapy resistance. This study suggests the necessity for clinical trials confirming the utility of the tyrosine kinase inhibitor, STI571, in ovarian advanced cancer patients with c-KIT overexpression when these patients have shown no clinical response to conventional chemotherapy.

C-KIT EXPRESSION AND CORRELATION WITH CHEMOTERAPY RESISTANCE IN OVARIAN CARCINOMA: AN IMMUNOCYTOCHEMICAL STUDY / M. RASPOLLINI; G. AMUNNI; A. VILLANUCCI; G. BARONI; A. TADDEI; G. TADDEI. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 15:(2004), pp. 594-597.

C-KIT EXPRESSION AND CORRELATION WITH CHEMOTERAPY RESISTANCE IN OVARIAN CARCINOMA: AN IMMUNOCYTOCHEMICAL STUDY

AMUNNI, GIANNI;TADDEI, ANTONIO;TADDEI, GIAN LUIGI
2004

Abstract

Abstract BACKGROUND: Recent studies have shown that several tumours express c-KIT, a growth factor receptor with tyrosine kinase activity; moreover, clinical results have shown the efficacy of the tyrosine kinase inhibitor, STI571, in c-KIT-positive tumours. The aim of this study was to determine the incidence and correlation with chemotherapy resistance of c-KIT expression in advanced serous, low grade of differentiation, ovarian carcinoma. PATIENTS AND METHODS: We performed an immunohistochemistry analysis of 56 patients with advanced serous ovarian carcinomas using archival paraffin-embedded specimens. RESULTS: Intense c-KIT immunostaining was observed in 51.7% of cases. c-KIT expression was statistically correlated with progression of disease after first-line chemotherapy (P = 0.029). CONCLUSIONS: c-KIT is also expressed in ovarian carcinoma and it is statistically correlated with chemotherapy resistance. This study suggests the necessity for clinical trials confirming the utility of the tyrosine kinase inhibitor, STI571, in ovarian advanced cancer patients with c-KIT overexpression when these patients have shown no clinical response to conventional chemotherapy.
15
594
597
M. RASPOLLINI; G. AMUNNI; A. VILLANUCCI; G. BARONI; A. TADDEI; G. TADDEI
File in questo prodotto:
File Dimensione Formato  
c-kit.pdf

accesso aperto

Tipologia: Altro
Licenza: Open Access
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF Visualizza/Apri

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2158/15722
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 44
social impact